Gts Securities LLC Incyte Corp Put Options Transaction History

Gts Securities LLC

5 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 13, 2024	SELL	$57.33 - $68.61 $126,126 - $150,942	-2,200 Reduced 15.71%	11,800 $779,000
Q2 2024 Aug 14, 2024	SELL	$51.18 - $63.75 $112,596 - $140,250	-2,200 Reduced 13.58%	14,000 $848,000
Q1 2024 May 15, 2024	BUY	$56.55 - $66.59 $508,950 - $599,310	9,000 Added 125.0%	16,200 $922,000
Q4 2023 Feb 14, 2024	SELL	$52.16 - $64.19 $286,880 - $353,045	-5,500 Reduced 43.31%	7,200 $452,000
Q3 2023 Nov 15, 2023	BUY	$57.77 - $65.93 $733,679 - $837,311	12,700 New	12,700 $733,000

644

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.4B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Gts Securities LLC, based on Form 13F filings with the SEC.

Stay updated on Gts Securities LLC with notifications on news.